Clinical trial · no report yet · Phase 3
KEYNOTE-B49
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- NCT04895358 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Neoplasms
- Interventions
- pembrolizumab; paclitaxel; nab-paclitaxel; liposomal doxorubicin; capecitabine; normal saline; dextrose
- Arms
- Pembrolizumab + Chemotherapy · Experimental
- Placebo + Chemotherapy · Active comparator
- Enrollment
- 342
- Primary outcomes
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jun 18, 2021
- Primary completion
- Apr 24, 2026
- Results posted
- No
- Registry record
- NCT04895358 · updated Jul 22, 2026